FY2030 Earnings Estimate for Valneva Issued By HC Wainwright

Valneva SE Sponsored ADR (NASDAQ:VALN) – HC Wainwright dropped their FY2030 earnings estimates for Valneva in a research report issued to clients and investors on Thursday, March 19th. HC Wainwright analyst B. Folkes now expects that the company will post earnings of $3.78 per share for the year, down from their prior estimate of $3.84. The consensus estimate for Valneva’s current full-year earnings is $0.13 per share.

Separately, Wall Street Zen cut Valneva from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $15.00.

Valneva Trading Down 1.6%

Shares of NASDAQ:VALN opened at $10.32 on Friday. The business’s 50 day simple moving average is $10.29 and its 200 day simple moving average is $9.68. Valneva has a 1 year low of $5.43 and a 1 year high of $12.25. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.38 and a quick ratio of 1.36. The company has a market capitalization of $888.66 million, a P/E ratio of -6.53 and a beta of 1.80.

Hedge Funds Weigh In On Valneva

Hedge funds and other institutional investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Valneva during the 4th quarter worth approximately $44,000. Marex Group plc acquired a new position in Valneva during the second quarter valued at approximately $64,000. XTX Topco Ltd bought a new stake in Valneva during the fourth quarter worth $94,000. VSM Wealth Advisory LLC boosted its holdings in shares of Valneva by 125.0% in the 3rd quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after purchasing an additional 5,000 shares in the last quarter. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Valneva in the 3rd quarter valued at $124,000. 11.39% of the stock is currently owned by institutional investors and hedge funds.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.